23:56 , Nov 3, 2017 |  BioCentury  |  Strategy

Broadening Novartis’ NET

Novartis AG’s proposed acquisition of Advanced Accelerator Applications S.A. would broaden the pharma’s neuroendocrine tumor franchise by providing it with a second-line agent -- Lutathera -- that addresses patients with progressive, symptomatic disease. On Oct....
23:27 , Aug 17, 2017 |  BC Innovations  |  Targets & Mechanisms

GRP-THINK AT THE BBB

Biogen Inc. has discovered antibodies in patients with a rare CNS autoimmune disease that could provide a new way to deliver mAbs across the blood-brain barrier, an application with wide-reaching ramifications for neurologic drug development....
07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
08:00 , Feb 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Genitourinary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Genitourinary disease Benign prostatic hyperplasia (BPH) Gastrin-releasing peptide (GRP) In vitro and rat studies suggest GRP antagonists could help treat BPH. In human prostate cell lines,...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Company News

Drais, Seldar, Astellas deal

Astellas and Drais partnered to form virtual company - Seldar Pharma Inc. - that will develop and commercialize Astellas' ASP7147 for irritable bowel syndrome with diarrhea. Seldar, which will be managed by Drais' executive team,...
00:47 , Jun 5, 2012 |  BC Extra  |  Company News

Astellas, Drais form newco to develop Astellas' IBS product

Astellas Pharma Inc. (Tokyo:4503) and Drais Pharmaceuticals Inc. (Bridgewater, N.J.) partnered to form virtual company -- Seldar Pharma Inc. -- that will develop and commercialize Astellas' ASP7147 for irritable bowel syndrome with diarrhea. Seldar, which...
08:00 , Feb 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Asthma Gastrin-releasing peptide (GRP) A study in mice suggests that inhibiting GRP signaling could help treat asthma. In mouse models of air pollution- and allergen-induced...
08:00 , Feb 10, 2011 |  BC Innovations  |  Targets & Mechanisms

Getting a GRP on asthma

Researchers at the Duke University School of Medicine have shown that a small molecule blocker of gastrin-releasing peptide, originally identified as a tumor growth inhibitor by researchers at the National Cancer Institute , attenuates multiple...
07:00 , Aug 27, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact nformation Neurology Pain Gastrin-releasing peptide receptor (GRPR; GRP-R) A study in mice suggests that targeting GRP-R could help relieve itching. In mice, intrathecal delivery of bombesin-saporin, a...
08:00 , Nov 17, 2008 |  BC Week In Review  |  Company News

Bracco Imaging S.p.A., Marillion deal

Bracco granted Marillion exclusive, worldwide rights to develop and commercialize 177Lu-AMBA to treat hormone-resistant prostate cancer (HRPC) and advanced breast cancer. The radiotherapeutic combined with an agonist of gastrin-releasing peptide receptor (GRP-R) is in Phase...